The tests add to the company’s existing PGx offerings for blood clotting, mental health, and immune suppression treatments.

The decision to register the therapy was supported by data from the Phase III TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 trials.

Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted ...

Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved ...

The Food and Drug Administration approved the drug, now marketed as Kisunla, in July of 2024. It's one of two drugs approved since 2023 that can clear the brain of sticky amyloid plaques ...

This was one woman's experience taking the drug Kisunla. Drugs can't stop Alzheimer's disease yet, but sometimes they can slow it down. MYRA SOLANO GARCIA: Things have just plateaued. I mean ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

Kisunla is the first amyloid-targeting therapy for people with Alzheimer's registered in Australia and the only amyloid plaque-targeting therapy with evidence to support stopping therapy when ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...